Research programme: antipsychotic therapeutics - Pfizer

Drug Profile

Research programme: antipsychotic therapeutics - Pfizer

Alternative Names: Compound 22; WAY-162545; WAY-163909; WAY-261240; WAY-629

Latest Information Update: 27 Sep 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Wyeth
  • Developer Pfizer
  • Class Chromans; Small molecules
  • Mechanism of Action Serotonin 2C receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Psychotic disorders

Most Recent Events

  • 16 Oct 2009 Wyeth has been acquired by Pfizer
  • 20 Aug 2009 Pharmacodynamics and pharmacokinetics data from a preclinical trial in Schizophrenia presented at the 238th National Meeting of the American Chemical Society (238th-ACS-2009) ,
  • 16 Aug 2009 Preclinical trials in Psychotic disorders in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top